Where extreme patient-derived biology becomes the blueprint for AI-guided small molecule design
From proprietary datasets on therapy-resistant, end-stage patient tissue, we combine extreme human biology with AI to design first-in-class small molecules for the highest unmet needs.
Built around patient biology that cannot be downloaded
An AI-native biotech combining proprietary platform technology by combining own generated patient-derived data with generative AI models to design novel small molecules, while building a diversified pipeline of proprietary small molecule assets across multiple disease areas.
Extreme biology first
>0
lines of prior therapy
We start where conventional discovery ends: end-stage, multi-line pre-treated tissues.
Data we own
>0K
proprietary datapoints
Exclusive access to tissue and clinical annotation, generated into 100K+ proprietary response datapoints.
Wetlab feedback loop
>0
molecules per program
400+ small molecules synthesised per program, each one tested in our own models and the results fed back into the next round of design.
A closed loop from patient tissue to designed molecule
Four stages, one loop. Tissue becomes models, models become proprietary response data, data becomes molecules — and every molecule tested feeds the next design cycle.
From patient tissue to designed molecule
Clinically relevant patient models
Treatment-resistant patient tissue is expanded into organoid models that preserve disease-relevant biology.
Proprietary data generation
Robotic live-cell imaging captures how patient-derived models respond to therapies and combinations with standard of care.
AI-guided molecular design
Response patterns combine with atom and quantum-level representations to design differentiated molecules.
Design, test and learn
Molecules are synthesised, tested and optimised in relevant models; every result returns to the platform.
One platform, three modalities
The same response data and design engine are applied across three small molecule modalities, chosen per target and per patient population.
Small molecules
Selective inhibitors designed against targets confirmed in treatment-resistant patient models, with selectivity measured against healthy counter-screens.
Differentiated assets in diverse therapeutic areas
Pancreatic, biliary tract and colorectal cancer
Gastric and esophageal cancer
Multiple solid tumors
Fibrotic diseases
Data is an asset in its own right: the response datasets generated in-house grow with every program.
Partnership opportunities
We work with partners who want access to patient-derived biology, proprietary response data and the molecules that come out of it.
Out-licensing
Diverse out-licensing options across our small molecule, molecular glue and payload programs.
Platform discovery partnerships
Joint programs built on our patient-derived models, response data and AI-guided design loop.
Investment
Opportunities to support the next stage of platform and pipeline development.
Supported by
The failure point of drug discovery is our starting point
info@sightera-biosciences.comDarwin incubator, Science Park Antwerp, Belgium